Vanguard Group Inc Aileron Therapeutics Inc Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.14 - $4.5 $68,336 - $2.2 Million	-488,121 Reduced 15.78%	2,605,107 $539,000
Q1 2022 May 13, 2022	SELL	$0.37 - $0.6 $123,167 - $199,730	-332,884 Reduced 9.72%	3,093,228 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$0.52 - $1.06 $9,806 - $19,990	-18,859 Reduced 0.55%	3,426,112 $1.93 Million
Q3 2021 Nov 12, 2021	BUY	$0.98 - $1.31 $4,251 - $5,682	4,338 Added 0.13%	3,444,971 $3.51 Million
Q2 2021 Aug 13, 2021	BUY	$1.06 - $1.43 $3.65 Million - $4.92 Million	3,440,633 New	3,440,633 $4.3 Million

213

Ticker ALRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,823,600
Market Cap $250M
Description
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advan...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.